SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology (AFJK) is currently experiencing extreme price swings and frequent trading halts, sparking active community discussion around its highly speculative nature as a "casino play." Many traders are focusing on its ultra-low float and high borrow rates, anticipating potential short squeezes, while others caution against a perceived "Chinese mafia pump" pattern often seen in similar volatile Chinese IPOs.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is actively trending following its FDA approval of NEREUS, marking the first new pharmacologic treatment for motion sickness in over four decades. The community is buzzing with speculation about NEREUS's potential to address GLP-1 induced nausea and vomiting, positioning the company as a key player in the rapidly expanding weight loss drug market and fueling buyout conversations. This milestone, alongside upcoming regulatory catalysts, is driving strong bullish sentiment and a re-evaluation of the company's long-term value.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its exceptionally active and dedicated community, passionately championing the "OG meme" narrative of Rage Comics. This committed base is consistently building out an ecosystem with projects like RageMaker and RageGames, aiming to onboard new users into crypto, and expresses strong conviction for substantial long-term growth within the broader market upswing.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co

Alpha Capital Acquisition Co. (ASPC) is trending with intense speculative interest, driven by community comparisons to recent low-float "Chinese SPAC" stocks that have experienced significant price volatility. Discussion is highly polarized between those anticipating a massive short squeeze due to high borrow rates and others warning of a potential pump-and-dump scenario. This dual narrative of extreme bullishness and caution, fueled by historical patterns of similar tickers, is generating considerable buzz.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is generating significant buzz in the trading community, largely driven by its exceptionally low float and high insider ownership. Many view it as the next potential 'squeeze' play, drawing strong comparisons to recent low-float SPACs like AFJK and ASPC which saw substantial upward movement. This unique structural setup fuels active discussion about its potential for rapid price action.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is trending due to a newly awarded, substantial contract for spacecraft docking systems, which has ignited significant trading volume and conversation among investors. The market is actively discussing the company's crucial position in the growing space infrastructure and defense sectors, along with the potential for a short squeeze given its notable short interest. Bullish sentiment prevails as many view Redwire as an undervalued play, poised for future growth despite prior dilution concerns.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending amid strong investor frustration over a prolonged stock decline to new record lows and persistent concerns about its interim leadership. The community is actively debating ongoing software complaints with its Gravity model and the company's ability to scale production effectively within the competitive EV market, contrasting its perceived vehicle quality with its underperforming stock.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amid analyst caution on its revenue outlook, largely attributed to crypto market weakness. Simultaneously, its holiday "free gift" giveaways are sparking considerable community debate, with users expressing both appreciation for small crypto rewards and frustration over app glitches. Conversations also revolve around its sensitivity to Bitcoin's price and its future as a broad fintech platform.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is experiencing extreme volatility due to the CME's recent margin hikes and impending Chinese export restrictions on silver, fueling intense market speculation. Bulls are aggressively anticipating a significant short squeeze, citing growing industrial demand from sectors like AI and a decoupling of physical versus paper market prices. Conversely, bears warn of an orchestrated pump-and-dump, predicting sharp corrections as leveraged positions face potential liquidation.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending amid a sharp stock price decline to 52-week lows, sparking intense debate among investors. Bulls emphasize strong fundamentals like a $1.4 billion contract and robust financials, while attributing the suppressed price to alleged manipulation and purchasing restrictions by major brokerage firms, fueling expectations of a future squeeze. Skeptics, however, point to management's communication issues and past perceived misleading announcements, questioning the company's ability to translate business growth into shareholder value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors...

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial TransCode...

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot...

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO TransCode Therapeutics presents preliminary data from its completed...

TransCode Therapeutics, Inc. (RNAZ) on Wednesday said that it has entered into a definitive agreement to acquire privately-held biotech firm Polynoma LLC from CK Life Sciences.The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/transcode-therapeutics-rnaz-announces-the-acquisition-of-polynoma-and-a-25-million-strategic-financing-by-a-subsidiary-of-ck-life-sciences-to-form-a-first-in-class-unique-immuno-oncology-and-metastatic-prevention-oncology-compa-302578286.html">announced</a> a $25 million investment from CK Life Sciences, expected to be used to advance the clinical development of its lead microRNA asset called TTX-MC138 into a mid-stage clinical trial. The candidate is believed to be a master regulator of metastatic cancer across multiple indications.Shares of the company soared 55% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNAZ">RNAZ stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.Polynoma is developing a late-stage candidate called seviprotimut-L, a vaccine aimed at melanoma patients who have limited options in stage IIB and IIC.“Between the two programs, we see a unique potential to augment seviprotimut-L's focus with our microRNA lead program, TTX-MC138, by addressing the micrometastases in stage IIB and IIC melanoma patients," TransCode’s new CEO, Philippe Calais, said.TransCode on Wednesday also announced that Calais has been appointed as the company CEO while remaining Chairman of the Board of Directors. Tom Fitzgerald stepped down as Interim CEO but remains CFO, it added.While there are no other changes to TransCode’s executive team, the company expects to retain several finance, development, and manufacturing professionals from Polynoma, it added.RNAZ stock is down by 87% this year and by 97% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stifel-hikes-price-target-on-tesla-after-fsd-v14-roll-out/ch6EKRbR3i9">Stifel Hikes Price Target On Tesla After FSD V14 Roll Out, Reiterates Hopes In Robotaxi</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset

The $25 million is expected to be used to advance the clinical development of its lead microRNA asset into a mid-stage clinical trial. 

Equity

The $25 million is expected to be used to advance the clinical development of its lead microRNA asset into a mid-stage clinical trial. 


Shares of TransCode Therapeutics Inc surged nearly 39% on Thursday after the company announced encouraging progress in its Phase 1a clinical trial of TTX-MC138, an experimental therapy targeting metastatic cancer.TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b (miR-10b), a genetic target believed to play a critical role in the emergence and progression of several metastatic cancers.&nbsp;According to TransCode, 13 patients have been treated with TTX-MC138 across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg.&nbsp;Eight patients remain on study, receiving additional doses during each 28-day treatment cycle, and two patients have been on therapy for approximately seven months with stable disease observed.No dose-limiting toxicities or significant safety concerns have been reported in the trial. Preliminary pharmacokinetic and pharmacodynamic data also align with earlier preclinical and Phase 0 findings.&nbsp;The results support advancing to the planned Phase 1b dose expansion, where researchers will further evaluate safety and early anti-tumor signals.The company’s financial position has been a key focus. As of April 2025, TransCode reported a cash balance of $5.81 million, with total liabilities exceeding assets by $2.02 million.&nbsp;Recent fundraising has helped shore up liquidity, including a $10.05 million registered direct offering in March 2025 and a $7.19 million equity raise in January.&nbsp;Last week, H.C. Wainwright lowered its price target on TransCode to $10 from $20 while maintaining a ‘Buy’ rating, according to The Fly.The firm cited recent equity raises as the reason for the revision but noted that its updated model assumes current funds are sufficient to support operations into 2026.Retail enthusiasm was evident on Stocktwits as sentiment was described as ‘extremely bullish,’ with message volume reaching ‘extremely high’ levels.&nbsp;Traders speculated on further upside, with some suggesting the stock could soon surpass the $1 mark and noting bullish chart patterns that could support another leg higher in after-hours trading.<stembedurl>https://stocktwits.com/ProfessorDman1/message/613317226</stembedurl><stembedurl>https://stocktwits.com/al_fred/message/613270466</stembedurl>Despite Thursday’s sharp rebound, TransCode shares remain down 84% year-to-date, far underperforming the broader market.&nbsp;By comparison, the Nasdaq is down 1.7%, while the Dow and S&amp;P 500 have declined 3.9% and 4.5%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

An electronic board displays information on recent fluctuations of market indices at the B3 Stock Exchange in Sao Paulo, Brazil, on April 7, 2025. (Photo by Cris Faga/NurPhoto via Getty Images)

TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside

TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns. 

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

RNAZ
TransCode Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest RNAZ News

RNAZTransCode Therapeutics Inc